Posting of Annual Report and Notice of 2023 AGM

Southampton, UK – 23 May 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that the Annual Report and Accounts for the year ended 31 December 2022 and Notice of its 2023 Annual General Meeting (AGM) have been posted to shareholders. These documents are available on the Company's website at

Annual General Meeting

Synairgen will host its AGM at 10:00 am BST on 29 June 2023 at Numis, 45 Gresham Street, London EC2V 7BF. The AGM will be held in person only.

Shareholders who are unable to attend the AGM but would like to exercise their right to vote on the resolutions being proposed should complete and submit an online proxy form to our registrar, Link Group, using their Signal shares online portal, by no later than 10:00 am BST on 27 June 2023. The form can be accessed and submitted at: If shareholders require any assistance in completing a proxy form, they should refer to the details set out in the AGM Notice.

The results of voting on all resolutions at the AGM will be announced via a Regulatory Information Service and the full results of the voting published on the Company's website, in the usual way, as soon as practicable after the conclusion of the AGM.

For further enquiries, please contact:

finnCap (NOMAD and Joint Broker)

Geoff Nash, Charlie Beeson (Corporate Finance)

Alice Lane, Sunil de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

Numis Securities Limited (Joint Broker)

Freddie Barnfield, Duncan Monteith, Euan Brown

Tel: + 44 (0) 20 7260 1000

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak

Tel: +44 (0) 20 3709 5700

MKC STRATEGIES, LLC (US Media Relations)

Mary Conway

Tel: +1 516-606-6545

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. The Company’s primary focus is developing SNG001 (inhaled interferon beta) for the treatment of severe viral lung infections as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA). Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see